Study #2021-0285
Phase IA/B Combination Study of ADI-PEG 20, Venetoclax and Azaciditine in Patients with Acute Myeloid Leukemia (AML)
MD Anderson Study Status
Enrolling
Treatment Agent
ADI-PEG 20
Description
Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy for such patients, and ADI-PEG 20 will be added to this regimen in a phase IA/B study.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia, Adult
Study phase:
Phase I
Physician name:
Gautam Borthakur
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.